Loading company…
Shanghai drug developer focused on new treatments for pain, inflammation and central nervous system diseases.
Based in Shanghai, China, and established in 2014, Shanghai SIMR Biotech Co., Ltd develops new drugs for pain, inflammation, depression and other central nervous system diseases. Its SR419 candidate has entered clinical phase II for neuropathic pain, while SR750 and SR1375 are in clinical phase I, with SR1375 aimed at diabetic macular edema. The company has an R&D centre of more than 3,000 square meters and branches in Guangdong, Jiangsu, Australia and America.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in